It’s still unclear whether the vaccine, which was cleared by UK health regulators last week, is effective at preventing Covid-19’s spread, according to the FDA staff report.
Countries have been buying up rights to multiple shots as an insurance policy against vaccines that might fail in clinical trials or not be produced in enough quantity.
Even if vaccines are as effective in the real world as they look in clinical trials, they can’t change the course of the pandemic overnight. We need reinforcements.
The recommendations on granting of authorisation will be made on three parameters — safety, quality and efficacy. The Drug Controller General of India will take the final decision.
Frontline healthcare staff, people over the age of 80 and care home workers will be among the first to get the vaccine as part of Phase 1 of the programme.
A few travel agencies are already formulating tour packages for Indians who want to travel to the UK and avail the recently-approved Pfizer-BioNTech Covid vaccine.
Health systems are gearing up to vaccinate hospital staff, but the side effects could put key workers out of commission for a couple of days while cases continue to surge.
Anthony Fauci said the UK drug regulator — Medicines and Healthcare products Regulatory Agency — took the data from the Pfizer company and rushed through the approval.
Spotlight now shifts to the high-stakes rollout of the vaccine. UK has ordered enough doses of the two-shot Pfizer-BioNTech vaccine to immunize 20 million people.
A theme has not yet emerged for BJP & people see lack of a contest, which makes it unexciting. For all these reasons, 2024 is turning out to be an unexpectedly theme-less election.
COMMENTS